NASDAQ Approval. The Company shall have filed with Nasdaq a Notification Form: Listing of Additional Shares for the listing of the Shares.
Appears in 5 contracts
Samples: Securities Purchase Agreement (Puma Biotechnology, Inc.), Securities Purchase Agreement (Puma Biotechnology, Inc.), Securities Purchase Agreement (Orgenesis Inc.)
NASDAQ Approval. The Company shall have filed with Nasdaq a Notification Form: Listing of Additional Shares for the listing of the Shares and the Underlying Shares.
Appears in 4 contracts
Samples: Securities Purchase Agreement (Orgenesis Inc.), Securities Purchase Agreement (Orgenesis Inc.), Securities Purchase Agreement (Orgenesis Inc.)
NASDAQ Approval. The Company shall have filed with Nasdaq NASDAQ a Notification Form: Listing of Additional Shares for the listing of the Shares., and, if required, shall have obtained stockholder approval of the issuance of the Shares hereunder
Appears in 2 contracts
Samples: Stock Purchase Agreement (Tokai Pharmaceuticals Inc), Stock Purchase Agreement (Tokai Pharmaceuticals Inc)
NASDAQ Approval. The Company shall have filed with Nasdaq a Notification Form: Listing of Additional Shares for the listing of the SharesShares and, with respect to each Additional Closing, for the listing of the Additional Shares purchased at such Additional Closing, which shall have been approved by Nasdaq.
Appears in 1 contract
Samples: Equity Purchase Agreement (Arcturus Therapeutics Ltd.)
NASDAQ Approval. The Company shall have filed with Nasdaq NASDAQ a Notification Form: Listing of Additional Shares for the listing of the Shares.
Appears in 1 contract
